The Diagnostic Technology Applied Research of CDK5RAP2 in Breast Cancer
Conditions
Breast Cancer
Conditions: official terms
Breast Neoplasms
Conditions: Keywords
expression of CDK5RAP2
Study Type
Observational
Study Phase
N/A
Study Design
Observational Model: Case Control, Time Perspective: Retrospective
Overall Status
Recruiting
Summary
Selected 400 cases of women with primary breast cancer who were treated with operation randomly, then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.
Detailed Description
The investigators selected 400 cases of women with primary breast cancer who were treated with operation randomly,then detect the expression of CDK5RAP2 of cancer tissue. At the same time randomly selected 100 women with primary breast cancer who were under neoadjuvant chemotherapy. Detect the expression of CDK5RAP2 before and after neoadjuvant chemotherapy.
Criteria for eligibility
Healthy Volunteers: No
Maximum Age: N/A
Minimum Age: N/A
Gender: Female
Criteria: Inclusion Criteria:

1. Provision of informed consent

2. Pathological confirmation of breast cancer

3. Tumor stage(TNM):T2-4bN0-3M0

4. ER(+) and/or PR(+).

5. Premenopausal woman.

6. Age≥40 years

7. Measurable disease as per RECIST criteria

8. Karnofsky≥70

9. Laboratory criteria:

- PLT≥100*109/L

- WBC≥4000/mm3

- HGB≥10g/dl

- ALT and AST<2*ULN

Exclusion Criteria:

1. Presence of metastatic disease.

2. Inflammatory breast cancer.

3. Bilateral breast cancer.

4. previous chemotherapy or hormonal therapy for current breast neoplasm.

5. other malignant tumor (concurrent or previous).

6. Pregnant woman.

7. Hypersensitive to any drug in CEF regimen or any ingredient of Zoladex.

8. Any severe systemic disease contraindicating chemotherapy.
Location
Jin Zhang
Tianjin, China
Status: Recruiting
Contact: Jin Zhang, Pro. - 86-022-23340123 - davidz9132002@yahoo.com
Start Date
January 2012
Completion Date
December 2015
Sponsors
Tianjin Medical University Cancer Institute and Hospital
Source
Tianjin Medical University Cancer Institute and Hospital
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page